📗 Cite This Artifact
Neurofeedback and Brain-Computer Interface Therapy for CBS/PSP
Neurofeedback and Brain-Computer Interface Therapy for CBS/PSP
Introduction
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurofeedback and Brain-Computer Interface Therapy for CBS/PSP</th>
</tr>
<tr>
<td class="label">Device</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Neuroflow</td>
<td>sLORETA</td>
</tr>
<tr>
<td class="label">Myndlift</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Brainbit</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Emotiv</td>
<td>EEG</td>
</tr>
</table>
Neurofeedback and Brain-Computer Interface (BCI) therapies represent emerging neuromodulation approaches for corticobasal degeneration (CBS) and progressive supranuclear palsy (PSP). These non-invasive and minimally invasive technologies aim to restore motor and cognitive function by modulating neural activity patterns. While research is still in early stages, evidence from Parkinson's disease (PD) and stroke rehabilitation suggests potential benefits for these tauopathies[@kober2023][@ranganathan2020].
EEG-Based Neurofeedback Protocols
Sensorimotor Rhythm (SMR) Training
Sensorimotor rhythm training targets the 12-15 Hz frequency band over the sensorimotor cortex. This protocol aims to enhance SMR activity while suppressing theta (4-8 Hz) and beta (18-22 Hz) bands, promoting more normalized cortical excitability[@sterman2020]:
Neurofeedback and Brain-Computer Interface Therapy for CBS/PSP
Introduction
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurofeedback and Brain-Computer Interface Therapy for CBS/PSP</th>
</tr>
<tr>
<td class="label">Device</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Neuroflow</td>
<td>sLORETA</td>
</tr>
<tr>
<td class="label">Myndlift</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Brainbit</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Emotiv</td>
<td>EEG</td>
</tr>
</table>
Neurofeedback and Brain-Computer Interface (BCI) therapies represent emerging neuromodulation approaches for corticobasal degeneration (CBS) and progressive supranuclear palsy (PSP). These non-invasive and minimally invasive technologies aim to restore motor and cognitive function by modulating neural activity patterns. While research is still in early stages, evidence from Parkinson's disease (PD) and stroke rehabilitation suggests potential benefits for these tauopathies[@kober2023][@ranganathan2020].
EEG-Based Neurofeedback Protocols
Sensorimotor Rhythm (SMR) Training
Sensorimotor rhythm training targets the 12-15 Hz frequency band over the sensorimotor cortex. This protocol aims to enhance SMR activity while suppressing theta (4-8 Hz) and beta (18-22 Hz) bands, promoting more normalized cortical excitability[@sterman2020]:
- Protocol: 30-40 sessions, 30 minutes each
- Target: Increase 12-15 Hz power over central cortex
- Indications: Motor impairment, cortical hyperexcitability
- Evidence: SMR training improves motor function in PD patients
Alpha-Theta Training
Alpha-theta neurofeedback targets the transition between relaxed wakefulness (alpha, 8-12 Hz) and drowsiness (theta, 4-8 Hz). This protocol has been explored for cognitive and mood symptoms in neurodegenerative conditions[@lubar2019]:
- Protocol: 20-40 sessions with gradual theta induction
- Target: Increase alpha power, moderate theta activity
- Indications: Cognitive impairment, mood disorders, sleep disturbances
Beta/Gamma Training
Beta-band (15-30 Hz) training aims to enhance motor activation and attention. This protocol may help address bradykinesia and cognitive slowing in CBS/PSP[@thompson2022]:
- Protocol: 20-30 sessions focusing on beta enhancement
- Target: Increase beta power over motor cortex
- Indications: Bradykinesia, reduced alertness
Motor Imagery Brain-Computer Interfaces
Motor Imagery Protocols
Motor imagery BCI allows patients to control external devices through imagined movements without actual motor output. This approach activates the same neural networks as motor execution, providing a potential rehabilitation pathway[@pichiorri2015]:
- Motor imagery types: Kinesthetic (feeling the movement) vs. visual (watching oneself move)
- BCI paradigms: Left/right hand, foot movement imagination
- Signal processing: Classification of EEG patterns corresponding to movement intent
Clinical Applications
Motor imagery BCI for CBS/PSP focuses on:
Evidence from Parkinson's Disease
Motor Function Improvements
Neurofeedback and BCI therapies have demonstrated benefits in PD:
- SMR training: Improves tremor, bradykinesia, and gait[@rosenblum2022]
- Motor imagery: Enhances motor planning and execution[@tinazzi2023]
- Beta oscillatory activity: Reduction correlates with clinical improvement
Cognitive Benefits
PD studies show neurofeedback may improve:
- Executive function and working memory
- Attention and processing speed
- Mood and quality of life
Neuroimaging Evidence
fMRI studies during neurofeedback show:
- Increased activation in supplementary motor area
- Reduced hyperactive beta oscillations
- Enhanced functional connectivity in motor networks
Evidence from Stroke Rehabilitation
Motor Recovery
Stroke rehabilitation research provides the strongest evidence for BCI-based motor recovery:
- BCI-coupled rehabilitation: Improved upper limb function in chronic stroke patients[@buch2022]
- Motor imagery with feedback: Enhances cortical reorganization
- Closed-loop systems: Real-time feedback improves motor learning
Mechanisms
Stroke and CBS/PSP share some motor impairment mechanisms:
- Cortical reorganization potential
- Motor network dysfunction
- Compensatory pathway activation
Translation to CBS/PSP
While stroke and CBS/PSP differ in pathophysiology, BCI approaches may help:
- Maintain function in remaining neural circuits
- Enhance compensatory mechanisms
- Provide neuroplasticity-promoting stimulation
Home Neurofeedback Devices
Approved Devices
Several home neurofeedback systems are available:
Home Protocol Considerations
- Supervision: Initial training by clinicians recommended
- Session duration: 20-30 minutes, 3-5 times weekly
- Progress monitoring: Regular clinical assessment
- Safety: No known serious adverse effects
Limitations for CBS/PSP
- Cognitive impairment may affect protocol compliance
- Motor impairments may interfere with device use
- Requires caregiver assistance in advanced cases
Research Status for CBS/PSP
Current Evidence Base
Research specifically targeting CBS/PSP is limited:
- Case studies: Small positive case series for neurofeedback
- PD extrapolation: Moderate evidence for similar motor symptoms
- Clinical trials: Few ongoing trials for tauopathies specifically
Ongoing Research
Current research initiatives include (NCT IDs TBD):
- (TBD): Neurofeedback for PSP (recruiting)
- University studies: BCI for motor impairment in atypical parkinsonism
- Device development: Next-generation neurofeedback systems
Challenges
Research limitations include:
- Disease rarity limiting trial enrollment
- Heterogeneous symptom presentation
- Progressive nature complicating outcome assessment
- Lack of validated outcome measures specific to neuromodulation
Mechanisms of Action
Neural Oscillation Modulation
Neurofeedback operates through:
Neuroplasticity Promotion
BCI and neurofeedback may promote neuroplasticity through:
Clinical Implementation
Patient Selection
Candidates for neurofeedback/BCI therapy:
- Mild to moderate motor impairment (Hoehn-Yahr 1-3)
- Intact cognitive function to follow protocols
- Motor imagery ability preserved
- Caregiver support available
Contraindications
- Severe cognitive impairment
- Active psychiatric conditions
- Epilepsy or seizure risk
- Inability to sit still for sessions
Treatment Protocol
Future Directions
Emerging Technologies
- Closed-loop neurofeedback: Real-time adaptation to brain state
- Multimodal integration: Combining EEG with fNIRS or EMG
- AI-assisted protocols: Machine learning optimization
- Transcranial current stimulation: Combined approaches
Research Priorities
- Randomized controlled trials in CBS/PSP
- Biomarker development for treatment response
- Optimal protocol standardization
- Long-term outcome studies
Cross-References
- [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
- [CBS/PSP Rehabilitation Guide](/therapeutics/cbs-psp-rehabilitation-guide)
- [Brain-Computer Interface Therapy](/therapeutics/brain-computer-interface-therapy)
- [PSP Rehabilitation Approaches](/mechanisms/psp-rehabilitation-approaches)
- [CBS Neuroinflammation](/mechanisms/cbs-neuroinflammation)
See Also
- [PSP Therapeutic Ideas](/therapeutics/psp-therapeutic-ideas)
- [CBS Emerging Treatments Pipeline](/therapeutics/cbs-emerging-treatments-pipeline)
- [Parkinson's Disease Treatment](/therapeutics/parkinsons-treatment)
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
- [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
- [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
Related Analyses:
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-neurofeedback-bci-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-2226ad46bd28 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neurofeedback-bci-cbs-psp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-neurofeedback-bci-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Neurofeedback and Brain-Computer Interface Therapy for CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-neurofeedback-bci-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-neurofeedback-bci-cbs-psp